Selvita S.A.

SLV.WA

Medical - Diagnostics & Research · Healthcare

Price

28.80 PLN

+0.15 (+0.52%)

Market Cap

528.5M PLN

Exchange

Warsaw Stock Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Mar 31, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Mixed

Stability

Mixed

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Selvita is a Polish drug discovery and research company that helps pharmaceutical and biotech firms develop new medicines. It offers contract research services — meaning other companies pay Selvita's scientists to run experiments and advance drug candidates on their behalf. Selvita also has its own small pipeline of early-stage cancer drugs it is developing internally.

The company earns money primarily by charging fees for research services, similar to how a consulting firm bills clients for work done. Selvita operates mainly in Europe, with a strong base in Kraków, Poland, and serves clients across Europe and North America. Its main competitive advantage is a large team of skilled scientists at a lower cost than labs in Western Europe or the US. However, the very thin operating margin of under 1% shows the business is barely profitable today, and the key risk is that rising labor costs in Poland could erode the cost advantage that attracts clients in the first place.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-15.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-458.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

103M PLN/ year

↑ Rising (+132% vs prior year)

28.2% of revenue

1.6x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

23.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

76M PLN cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Selvita S.A. is putting 28% of revenue into R&D and that number is rising. That's 1.6x the sector average. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 18.4M (2021) → 18.4M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-4.8%

Thin — -4.8% gross margin

Profit after running costs

Operating Margin

-9.0%

Losing money on operations — -9.0%

Return on the money invested

ROCE

0.7%

Weak — 0.7% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-1.2%

Shrinking sales (-1.2% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

16.8%

Converts sales into free cash efficiently (16.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.31

Conservative — low debt load (0.31)

Covers its interest

Interest Cover

0.23x

Dangerous — barely covers interest (0.2x)

Interest coverage below 1. Their profits don't cover the interest bill.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial